HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides
Denis R. St. Laurent(Bristol-Myers Squibb (United States)), Lawrence B. Snyder(Arvinas (United States)), Jay O. Knipe(Bristol-Myers Squibb (United States)), Mengping Liu(China University of Geosciences (Beijing)), Makonen Belema, Jason T. Goodrich(Bristol-Myers Squibb (United States)), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), Donald R. O’Boyle(Bristol-Myers Squibb (United States)), Lourdes Valera(Bristol-Myers Squibb (United States)), Xuejie Yang(Chinese Academy of Sciences), Omar D. Lopez(Bristol-Myers Squibb (United States)), Peter T. Nower, Yuping Qiu(Southwest Forestry University), Jin-Hua Sun(University of Science and Technology of China), J. Romine(Bristol-Myers Squibb (United States)), Michael H. Serrano‐Wu(Broad Institute), Min Gao(Shandong First Medical University), Fukang Yang(Bristol-Myers Squibb (United States)), Ramesh Kakarla(Bristol-Myers Squibb (United States)), Van N. Nguyen, Julie A. Lemm(Bristol-Myers Squibb (United States))
Cited by 27
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Applications of fluorine-containing amino acids for drug design
|European Journal of Medicinal Chemistry|2019|238
Identification of Hepatitis C Virus NS5A Inhibitors
|Journal of Virology|2009|196
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
|Antimicrobial Agents and Chemotherapy|2012|186